Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
The average brokerage recommendation (ABR) for Johnson & Johnson (JNJ) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
JNJ is up nearly 12% YTD as strong oncology drug growth, MedTech demand and pipeline advances help offset Stelara patent-loss pressure.
Boston Scientific (BSX) previously commanded a premium valuation based on its transition toward a high-margin cardiovascular powerhouse, driven by its FARAPULSE Pulsed Field Ablation (PFA) system and WATCHMAN cardiac implant. In Q1 2026, the cardiovascular segment posted a strong 13.5% reported growth. However, intense competition from Medtronic (MDT) and Johnson & Johnson (JNJ) has challenged this hyper-growth thesis. Johnson & Johnson's Varipulse system integrates directly into the dominant CA
Eli Lilly has outpaced the Nasdaq Composite over the past year, and analysts remain very confident in its longer-term trajectory.
Johnson & Johnson has outperformed the Dow Jones over the past year, and analysts remain moderately optimistic about the stock’s outlook.
Johnson & Johnson seems to have perfected the art of the biotech deal. Rather than spending billions on acquisitions, it has built much of its pharma empire through partnerships that capture huge upside for bargain prices. A biotech partnership is a bit like an open relationship: Your partner can always fall in love with someone else.
Black Diamond is expanding silevertinib into glioblastoma, adding long-term CNS-driven optionality while NSCLC remains the nearer-term focus.
BDTX's Q1 beat and cash runway into 2028 keep focus on silevertinib's clinical durability, CNS profile and pivotal path.
Black Diamond's May 2026 silevertinib update showed steady NSCLC response rates, CNS activity and dose progress, but durability data remain early.
PFE is banking on new launches, Seagen assets and pipeline progress to counter a looming patent cliff through 2030.
The acquisition is the latest in a series of agreements between DePuy Synthes and organizations associated with entrepreneur Stéphane Lavallée.
Don't be too quick to give up on the industry.
Johnson & Johnson (JNJ) is in focus after a Minnesota jury included the company in a US$10.2 million mesothelioma verdict tied to asbestos contaminated cosmetic talc products, adding to its broader talc related legal exposure. See our latest analysis for Johnson & Johnson. Despite headlines around talc litigation, Johnson & Johnson’s stock has had a 13.02% year to date share price return. Its 1 year total shareholder return of 55.84% points to strong momentum built over a longer stretch, even...
The Dow gave back its opening gains, with healthcare stocks a big drag. The blue-chip index was trading flat, while the S&P 500 was up 0.9%, and the Nasdaq rose 1.4%. UnitedHealth Group and Amgen, among the Dow's top five stocks, were down by nearly 3% and 0.4%, respectively.
A 50-year-old woman planning to retire at 70 on the equivalent of $80,000 in today’s purchasing power is actually targeting a much larger nominal income figure. Assuming long-run inflation averages 3% annually, maintaining that same lifestyle 20 years from now would require roughly $144,500 per year in nominal dollars. That is the income her portfolio needs ... Inflation Adjusted Dividend Income: How to Replace $80,000 in Today’s Dollars 20 Years From Now
DePuy Synthes, a subsidiary of Johnson & Johnson (NYSE:JNJ), announced an exclusive distribution agreement with CGBIO for the bone graft substitute NOVOSIS across the United States, Canada and Australia. NOVOSIS designed for multiple orthopaedic applicationsNOVOSIS is a growth factor-based bone graft substitute intended for use in a range of orthopaedic procedures, including spinal surgery, craniomaxillofacial procedures and trauma-related applications.
In the Large-Cap Pharmaceuticals industry, LLY, J&J, NVO and BAYRY are worth retaining as the industry shows some recovery.
JPMorgan says low-volatility stocks have underperformed this year, are ready to bust out no matter what the macro backdrop looks like.
US stocks are set to open higher after Monday’s Memorial Day holiday, catching up with strong gains elsewhere as investors tentatively welcome signs of progress towards a ceasefire deal between the US, Israel and Iran. Nasdaq futures were the strongest, up 1%, while gains for the Dow Jones...
A $450,000 portfolio generating a 6% blended yield produces about $27,000 per year in income. For many early retirees between ages 55 and 65, that can function as a financial bridge between leaving full-time work and the arrival of Social Security and Medicare benefits. The underlying math is straightforward: $27,000 divided by a 6% yield ... How $450,000 Can Deliver a $27,000 Paycheck Without Working a Day
Johnson & Johnson (NYSE:JNJ) has secured naming rights for the Johnson & Johnson Exchange at the new NJ Innovation Hub in New Brunswick. The company announced a major partnership focused on early stage biomedical work and entrepreneurship within New Jersey's life sciences sector. The Johnson & Johnson Exchange is intended to connect academia, founders, and investors in one of the US's most active biotechnology ecosystems. For investors watching NYSE:JNJ, this move highlights how the company...
Johnson & Johnson sells products that are necessities, not just nice-to-haves.
A California retiree with a $1 million dividend portfolio earning a 5% blended yield grosses $50,000 in annual income. After federal qualified-dividend tax and California’s state income tax, that number drops sharply. California treats dividends as ordinary income at the state level, with marginal rates running from 9.3% to 13.3%. The math is what separates ... What a $1 Million Dividend Portfolio Actually Pays After Federal AND State Taxes in California
The Vanguard Dividend Appreciation Index Fund ETF Shares (NYSEARCA:VIG) is having a quieter year than its big-cap dividend-growth reputation suggests, with shares around $229 and a 5% year-to-date gain trailing the broader market. The 12-month picture is stronger at almost 17%, but the recent flattening tells you something important: VIG’s dividend-growth playbook is being squeezed ... VIG Investors: Watch the 10-Year Treasury Yield This Week—4.75% Is the Danger Line
The pitch for the FT Vest S&P 500 Dividend Aristocrats Target Income ETF (NYSEARCA:KNG) lands cleanly in retirement conversations. You own 69 Dividend Aristocrats, the manager writes monthly call options against every position, and the fund distributes roughly 8.6%. KNG turns a basket of slow-growing quality compounders into something resembling a bond substitute. The yield, ... KNG’s 8.6 Percent Yield Comes From Selling Calls on Dividend Aristocrats, And It Has Lagged NOBL Since 2018
Johnson & Johnson (NYSE:JNJ) and AbbVie (NYSE:ABBV) both posted Q1 2026 results that beat revenue expectations and prompted raised full-year guidance. JNJ leaned on a diversified pharma plus MedTech engine. AbbVie leaned almost entirely on immunology. Both face biosimilar headwinds, yet each chose a different way to outgrow them. TREMFYA and Cardiovascular Carry JNJ. Skyrizi ... Two Paths to Growth: Johnson & Johnson vs AbbVie
Johnson & Johnson (NYSE:JNJ) was found liable in a Minnesota cosmetic talc mesothelioma lawsuit, sharing responsibility with other manufacturers. The jury verdict resulted in a significant personal injury award for the plaintiff, expanding the scope of talc related legal exposure for the company. This case adds to Johnson & Johnson’s ongoing talc litigation and raises fresh questions about future legal and reputational risk. Johnson & Johnson, trading at around $234.34 per share, has...
Trading with an implied upside of 124.7% and an RSI of 39.6, Stereotaxis, Inc. (NYSEAMERICAN:STXS) has emerged as a notable oversold play in the AI sector. However, more recently, Piper Sandler lowered its price target on Stereotaxis, Inc. (NYSEAMERICAN:STXS) to $3.5 from $4.0 on May 13, 2026, while keeping an “Overweight” rating. The firm pointed […]
A retired couple with $700,000 in a taxable brokerage account could potentially generate close to $19,000 a year in combined dividend income and tax savings by using a direct-indexing strategy. Part of that benefit comes from ordinary stock dividends. The rest comes from tax-loss harvesting, which is the main advantage of direct indexing over a ... How Direct Indexing May Produce $19,000 in Annual Income on a $700,000 Portfolio
Income investors holding the VictoryShares US Large Cap High Div Volatility Wtd ETF (NYSEARCA:CDL) own a fund built around one premise: large American companies with stable share prices tend to pay reliable dividends. CDL distributes cash monthly and paid $2.29 per share in 2025 against a current share price of roughly $76. With Treasury yields ... CDL’s $2.29 annual dividend beats Treasury yields despite rising interest rates
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.